IMGN - ImmunoGen, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.8700
-0.0900 (-4.59%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.9600
Open1.9300
Bid1.8700 x 43500
Ask1.8800 x 3000
Day's Range1.8600 - 1.9500
52 Week Range1.7600 - 12.3100
Volume2,529,570
Avg. Volume3,441,847
Market Cap279.623M
Beta (3Y Monthly)2.31
PE Ratio (TTM)N/A
EPS (TTM)-1.2060
Earnings DateJul 25, 2019 - Jul 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.83
Trade prices are not sourced from all markets
  • ACCESSWIRE21 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN

    NEW YORK, NY / ACCESSWIRE / June 3, 2019 / Pomerantz LLP is investigating claims on behalf of investors of ImmunoGen, Inc. ("ImmunoGen" or the "Company") (IMGN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether ImmunoGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • Why Is ImmunoGen (IMGN) Down 26% Since Last Earnings Report?
    Zacks22 days ago

    Why Is ImmunoGen (IMGN) Down 26% Since Last Earnings Report?

    ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Benzinga29 days ago

    The Week Ahead In Biotech: ASCO Presentations In The Spotlight

    After two successive weeks of losses, biotech stocks slowly clawed back. Multiple conference presentations, independent clinical trial readouts and a few FDA decisions marked the key events in the biotech ...

  • Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN
    Zackslast month

    Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN

    Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

  • Benzingalast month

    Bulls And Bears Of The Week: Apple, Chevron, FedEx, Uber And More

    Benzinga has examined prospects for many investor favorite stocks over the past week. Bearish calls included biotechs and a recent IPO. Furthermore, investors also saw mixed economic numbers, as well as positive surprises in quarterly reports and initial public offerings, bad news for a market darling from the Supreme Court, and fresh news for whale watchers.

  • ImmunoGen Plunges as FDA Recommends New Study for Lead Drug
    Zackslast month

    ImmunoGen Plunges as FDA Recommends New Study for Lead Drug

    FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.

  • What Analysts Recommend for IMGN after Its Q1 Results
    Market Realistlast month

    What Analysts Recommend for IMGN after Its Q1 Results

    Why Did Immunogen Stock Crash on May 15?(Continued from Prior Part)Recent share price movementsOn May 15, Immunogen (IMGN) issued a press release announcing mature data from its FORWARD II expansion cohort, which is evaluating the combination of

  • Why Immunogen Was Down by More than 30% on May 15
    Market Realistlast month

    Why Immunogen Was Down by More than 30% on May 15

    Why Did Immunogen Stock Crash on May 15?Recent regulatory updateOn May 15, Immunogen (IMGN) issued a press release announcing the FDA’s recommendation to conduct a new Phase 3 trial evaluating mirvetuximab soravtansine monotherapy in high folate

  • Why The Children's Place, Agilent Technologies, and Immunogen Slumped Today
    Motley Foollast month

    Why The Children's Place, Agilent Technologies, and Immunogen Slumped Today

    Despite a solid gain in the market, these companies struggled.

  • Why ImmunoGen Shares Are Crashing Today
    Motley Foollast month

    Why ImmunoGen Shares Are Crashing Today

    Disappointing news from the FDA means that the biotech company is further from potentially winning approval for its lead drug candidate.

  • TheStreet.comlast month

    ImmunoGen Plunges as FDA Rejects Fast-Track Approval for Cancer Drug

    plunged more than 30% on Wednesday after the company revealed that the U.S. Food and Drug Administration has recommended further trials to "evaluate the safety and efficacy" of one of its cancer-fighting treatments. ImmunoGen said in statement that it had requested a meeting with FDA officials to discuss the results of its Phase 3 FORWARD I trial and a potential path to registration for mirvetuximab monotherapy - a treatment it has been developing for patients with certain forms of ovarian cancer. In response, the FDA told ImmunoGen that because the data results produced to date have not been able to meet expectations, "... the study could not be used to support an application for accelerated approval," ImmunoGen said in a statement.

  • MarketWatchlast month

    ImmunoGen stock down more than 30% after FDA suggests conducting new Phase 3 trial for ovarian cancer drug

    Shares of ImmunoGen, Inc. fell 32% in premarket trade Wednesday after the company said the U.S. Food and Drug Administration recommended conducting a new Phase 3 trial of its ovarian cancer drug, mirvetuximab soravtansine. A recent trial looking at the drug as an ovarian cancer therapy did not meet its primary endpoint. ImmunoGen met with the FDA this past week to discuss the trial and a potential path forward, and the agency provided guidance on trial design and endpoints, the company said. "Our meeting with FDA enabled us to clarify a regulatory path forward for mirvetuximab and we are evaluating all avenues to bring this promising therapy to ovarian cancer patients," Immunogen Chief Executive Mark Enyedy said in a statement. The Waltham, Mass.-based biotech has been working on mirvetuximab as a potential treatment for patients with ovarian cancer who haven't responded to platinum treatment and who also test positive for high folate receptor α. Shares of the biotech have fallen 34% so far this year through Tuesday, while the S&P 500 has gained 13%.

  • Business Wirelast month

    ImmunoGen Provides Regulatory Update on Mirvetuximab Soravtansine Monotherapy in Ovarian Cancer

    ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the United States Food and Drug Administration (FDA) has recommended that the Company conduct a new Phase 3 randomized trial to evaluate the safety and efficacy of mirvetuximab soravtansine in patients with high folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer as part of a Type C meeting held this week. ImmunoGen requested the meeting to discuss the results of the Phase 3 FORWARD I trial and a potential path to registration for mirvetuximab monotherapy. FDA acknowledged that platinum-resistant ovarian cancer is a disease with unmet need, provided guidance regarding the design and endpoints of a potential registration study, and encouraged the Company to return to discuss a proposed study design.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of IMGN earnings conference call or presentation 3-May-19 12:00pm GMT

    Q1 2019 ImmunoGen Inc Earnings Call

  • ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1
    Zacks2 months ago

    ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1

    ImmunoGen (IMGN) reports wider-than-expected loss in Q1 and misses revenue estimates.

  • Is ImmunoGen, Inc. (IMGN) A Good Stock To Buy?
    Insider Monkey2 months ago

    Is ImmunoGen, Inc. (IMGN) A Good Stock To Buy?

    The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]

  • Immunogen Inc (IMGN) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Immunogen Inc (IMGN) Q1 2019 Earnings Call Transcript

    IMGN earnings call for the period ending March 31, 2019.

  • ImmunoGen (IMGN) Reports Q1 Loss, Lags Revenue Estimates
    Zacks2 months ago

    ImmunoGen (IMGN) Reports Q1 Loss, Lags Revenue Estimates

    ImmunoGen (IMGN) delivered earnings and revenue surprises of 3.23% and -14.13%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    ImmunoGen: 1Q Earnings Snapshot

    On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 30 cents. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...

  • Business Wire2 months ago

    ImmunoGen Reports Recent Progress and First Quarter 2019 Financial Results

    Encouraging Efficacy Signal Observed in Pre-Specified Subset of Patients in Phase 3 FORWARD I Study; Company to Meet with Regulators this Quarter to Discuss Potential Path Forward